Synthesis method of 5-bromo-3-cyclopropyl-1H-pyrrolo [2, 3-b] pyridine

Through a simplified three-step reaction method, using Compound 1 as a raw material, 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine was successfully synthesized, solving the loss of the synthesis route of the compound in the prior art. The problem of this method achieves the synthesis effect of low cost, high yield and mild reaction conditions.

CN118930535APending Publication Date: 2024-11-12上海毕得医药科技股份有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410977704.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The lack of synthesis methods of 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine in the prior art has resulted in limited development and utilization of this compound.

Method used

Three-step reaction method is adopted: first, by introducing a protective group (trimethylsilicon) ethoxymethyl reaction, followed by cross-coupling reaction, and finally removing the protective group (trimethylsilicon) ethoxymethyl reaction, using compounds 1 (5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine) was used as a starting material to simplify the steps and reduce the reaction conditions.

Benefits of technology

A brief synthesis step, low cost, mild reaction conditions and high yield were achieved, with high safety, and the target compound 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine was obtained.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930535A_ABST
    Figure CN118930535A_ABST
Patent Text Reader

Abstract

The invention discloses a synthesis method of 5-bromine-3-cyclopropyl-1H-pyrrolo [2, 3-b] pyridine, which comprises the following steps: by taking a compound 1 (5-bromine-3-iodine-1H-pyrrolo [2, 3-b] pyridine) as a raw material, sequentially carrying out a protective group (trimethylsilyl) ethyoxyl methyl introduction reaction, a cross-coupling reaction and a protective group (trimethylsilyl) ethyoxyl methyl removal reaction, thereby obtaining the 5-bromine-3-cyclopropyl-1H-pyrrolo [2, 3-b] pyridine. And the 5-bromo-3-cyclopropyl-1H-pyrrolo [2, 3-b] pyridine is obtained through the three steps of reaction. According to the synthesis method, the target compound is obtained through short steps, simple and convenient operation, relatively mild reaction conditions and high yield, the synthesis process is low in cost and low in potential safety hazard, and a potential route is provided for technological synthesis of the 5-bromo-3-cyclopropyl-1H-pyrrolo [2, 3-b] pyridine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine. Background Art

[0002] Cyclopropylpyrrolopyridine compounds are an important class of organic compounds with wide applications in the fields of life sciences, medicine, chemistry, etc. For example, 4-bromo-2-cyclopropyl-1H-pyrrolo[2,3-b]pyridine is used as a key intermediate in the synthesis of PI3 kinase inhibitors in patent WO2009 / 147188, which can be used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), allergic diseases such as allergic rhinitis and atopic dermatitis, autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, inflammatory diseases such as inflammatory bowel disease, cardiovascular diseases such as thrombosis and atherosclerosis, hematological malignancies, cystic fibrosis, neurodegenerative diseases, pancreatitis, kidney disease, platelet aggregation, cancer, transplant rejection, lung injury, pain such as pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, diabetic neuropathy changes, inflammatory neuralgia, trigeminal neuralgia and central pain, etc.; in patent WO2022 / 216717, it is used for the synthesis of citron kinase inhibitors, which can be used to treat cancers such as medulloblastoma or prostate cancer; 2-cyclopropyl-1H-pyrrolo[2,3-b]pyridine is also used as a key intermediate in WO2008 / 034860 ​​for the synthesis of IKK2 inhibitors, which can be used to treat diseases associated with inappropriate IKK2 (also known as IKKβ) activity, especially for the treatment and prevention of diseases mediated by the IKK2 mechanism, such as rheumatoid arthritis, asthma, rhinitis and COPD (chronic obstructive pulmonary disease); in WO2022 / 169974, it is used for the synthesis of URATI inhibitors, which can be used to treat diseases such as gout.

[0003] Cyclopropylpyrrolopyridine compounds show great economic potential. 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine, as one of the compounds, also has high economic efficiency. In the prior art, the synthesis route of 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine has not been reported. Therefore, further research on its synthesis method will not only be beneficial to the development of this compound, but also will contribute to the development and utilization of cyclopropylpyrrolopyridine compounds. Summary of the invention

[0004] In view of the above problems existing in the prior art, the object of the present invention is to provide a method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine, which has low cost, short steps, easy operation, relatively mild reaction conditions, low safety risks and ideal yield.

[0005] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0006] The present invention provides a method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine, and the synthetic route of the synthetic method is as follows:

[0007]

[0008] Specifically, the steps include:

[0009] (1) Compound 1 is dissolved in an organic solvent I, and a base a and 2-(trimethylsilyl)ethoxymethyl chloride are added at -5 to 5°C. After the addition is complete, the mixture is reacted at 15 to 60°C for 10 to 40 hours. After the reaction is complete, the resulting reaction solution is post-treated to obtain Compound 2;

[0010] (2) Compound 2, zinc chloride and organic solvent II are mixed evenly, and a portion of cyclopropylmagnesium bromide solution is added under the protection of an inert gas. After the addition is complete, a palladium catalyst is added, and the temperature is raised to 40 to 60° C., and the remaining cyclopropylmagnesium bromide solution is added. After the addition is completed, the reaction is carried out at 15 to 60° C. for 0.5 to 3 hours. After the reaction is completed, the resulting reaction solution is post-treated to obtain compound 3;

[0011] (3) Compound 3 is dissolved in a hydrochloric acid ethyl acetate solution, stirred at 15-60°C for 8-16 hours, the resulting reaction solution is spun dry, then dissolved in dichloromethane, base b is added, stirred at 15-60°C for 2-4 hours; then ammonia water is added, stirred at 15-60°C for 8-16 hours; after the reaction is completed, the resulting reaction solution is post-treated to obtain the target compound 4, i.e., 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine.

[0012] Preferably, in step (1), the organic solvent I is selected from one or more of acetonitrile, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, toluene, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide or N-methylpyrrolidone.

[0013] Preferably, in step (1), the base a is selected from one or more of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium acetate, sodium tert-butoxide or potassium tert-butoxide.

[0014] Preferably, in step (1), the molar ratio of compound 1, base a and 2-(trimethylsilyl)ethoxymethyl chloride is 1:1.8-2.2:1-1.4.

[0015] More preferably, in step (1), the base a is potassium carbonate, and the molar ratio of compound 1, potassium carbonate and 2-(trimethylsilyl)ethoxymethyl chloride is 1:2:1.2.

[0016] Preferably, in step (2), the organic solvent II is selected from one or more of tetrahydrofuran, diethyl ether or methyl tert-butyl ether.

[0017] Preferably, in step (2), the inert gas is nitrogen and / or argon.

[0018] Preferably, in step (2), the palladium catalyst is tetrakis(triphenylphosphine)palladium and / or tris(dibenzylideneacetone)dipalladium.

[0019] Preferably, in step (2), the mass volume ratio of the compound 2 to the organic solvent II is 1:5-40 g / mL.

[0020] Preferably, in step (2), the molar ratio of the compound 2, zinc chloride, palladium catalyst and cyclopropylmagnesium bromide is 1:0.4-0.6:0.02-0.08:2.5-3.

[0021] More preferably, in step (2), the palladium catalyst is tetrakis(triphenylphosphine)palladium, and the molar ratio of compound 2, zinc chloride, tetrakis(triphenylphosphine)palladium and cyclopropylmagnesium bromide is 1:0.5:0.05:2.7.

[0022] Preferably, in step (3), the base b is selected from one or more of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium acetate, sodium tert-butoxide or potassium tert-butoxide.

[0023] Preferably, in step (3), the molar ratio of compound 3 to base b is 1:2-6.

[0024] More preferably, in step (3), the base b is potassium carbonate, and the molar ratio of compound 3 to potassium carbonate is 1:4.

[0025] Preferably, in step (1), the post-treatment process comprises: adding ice water to the reaction solution, extracting with organic solvent III, combining the organic phases, drying, filtering, concentrating, and purifying the crude product to obtain compound 2.

[0026] Preferably, in step (2), the post-treatment process comprises: adding water to the reaction solution, extracting with an organic solvent IV, combining the organic phases, drying, filtering, concentrating, and purifying the crude product to obtain compound 3.

[0027] Preferably, in step (3), the post-treatment process comprises: adding water to the reaction solution, extracting with an organic solvent V, combining the organic phases, drying, filtering, concentrating, and purifying the crude product to obtain the target compound 4.

[0028] More preferably, the organic solvent III is selected from one or more of ethyl acetate, butyl acetate, chloroform, toluene, dichloromethane, and dichloroethane;

[0029] and / or the organic solvent IV is selected from one or more of isooctane, cyclohexane, hexane, petroleum ether, n-pentane and isopentane;

[0030] And / or the organic solvent V is selected from one or more of isooctane, cyclohexane, hexane, petroleum ether, n-pentane and isopentane.

[0031] Compared with the prior art, the present invention has the following beneficial effects:

[0032] The invention provides a method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine. The method comprises the following steps: using compound 1 (5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine) as a raw material, sequentially carrying out a protective group (trimethylsilyl)ethoxymethyl introduction reaction, a cross-coupling reaction and a protective group (trimethylsilyl)ethoxymethyl removal reaction, and obtaining 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine. The method comprises the following steps: using a simple operation and using relatively mild reaction conditions to obtain a target compound with a high yield. The method provides a potential route for the process synthesis of 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 It is the H NMR spectrum of compound 3 in Example 1.

[0034] Figure 2 It is the H NMR spectrum of compound 4 in Example 1. DETAILED DESCRIPTION

[0035] In order to more fully understand and demonstrate the technical solutions, purposes and advantages of the present invention, the technical effects produced by the present invention are further described in detail and completely in conjunction with specific embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all. It should be pointed out that for those of ordinary skill in the art, other embodiments obtained without departing from the concept of the present invention all belong to the protection scope of the present invention.

[0036] Unless otherwise specified in the following examples, all reagents and materials used were commercially available.

[0037] Example 1

[0038] This embodiment provides a method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine, and the synthetic route is as follows:

[0039]

[0040] The specific steps are:

[0041] (1) Compound 1 (300.00 g, 928.99 mmol, 1.0 eq) and solvent N,N-dimethylformamide (3.0 L) were added to a 5 L three-necked flask, potassium carbonate (256.78 g, 1.86 mol, 2.00 eq) was added under an ice-water bath, and 2-(trimethylsilyl)ethoxymethyl chloride (185.86 g, 1.11 mol, 1.20 eq) was added dropwise. After the addition was completed, the reaction mixture was reacted at room temperature for 12 h. After the reaction was completed, ice water (2.0 L) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (2.0 L×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography to obtain compound 2 (white solid, weight 381.00 g, purity 97%, yield 88%).

[0042] (2) Compound 2 (300.00 g, 661.97 mmol, 1.0 eq), zinc chloride (45.11 g, 330.98 mmol, 0.50 eq), and tetrahydrofuran (3.0 L) were added to a 5 L three-necked flask. Cyclopropylmagnesium bromide solution (661.97 mL, 1.00 eq, 1.00 M in THF) was slowly added dropwise under argon protection. After the addition was complete, tetrakis(triphenylphosphine)palladium (38.25 g, 33.10 mmol, 0.05 eq) was added. The temperature was raised to 50 °C, and cyclopropylmagnesium bromide solution (1.13 L, 1.70 eq, 1.00 M in THF) was added. After the addition was complete, the mixture was reacted at room temperature for 0.5 h. After the reaction was completed, water (4.0 L) was added to the reaction solution, and the mixture was extracted three times with petroleum ether (3.0 L×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography to obtain compound 3 (white solid, weight 229.90 g, purity 96%, yield 91%).

[0043] The H NMR spectrum of compound 3 is as follows Figure 1 The obtained characterization data are as follows:

[0044] 1H NMR(400MHz,cdcl3)δ8.32(d,J=2.1Hz,1H),8.09(d,J=2.2Hz,1H),7.04(s,1H),5.56(s,2H),3.4 9(dd,J=10.9,5.6Hz,2H),1.91-1.82(m,1H),0.92-0.85(m,4H),0.67-0.56(m,2H),-0.07(s,9H).

[0045] (3) Add compound 3 (140.00 g, 308.92 mmol, 1.0 eq) and 1M hydrochloric acid ethyl acetate solution (700 mL) to a 2L three-necked flask, and stir at room temperature for 12 h. The reaction solution was spun dry, then dissolved in dichloromethane (700 mL), potassium carbonate (170.78 g, 1.24 mol, 4.00 eq) was added, and the reaction was stirred at room temperature for 3 h. Ammonia water (70 mL) was added, and the reaction was stirred at room temperature for 12 h. After the reaction was completed, water (1.0 L) was added to the reaction solution, and petroleum ether was extracted three times (1.0 L × 3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography to obtain the target compound 4 (5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine, white solid, weight 109.30 g, purity 98%, yield 94%).

[0046] The H NMR spectrum of 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine is as follows Figure 2 The obtained characterization data are as follows:

[0047] 1 H NMR (400MHz, dmso) δ11.55(s,1H),8.21(dd,J=18.1,2.0Hz,2H),7.24(d,J=2.4Hz,1H),1.97-1.87(m,1H),0.88-0.78(m,2H),0.66-0.55(m,2H).

[0048] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine, characterized in that: The synthetic route of the synthetic method is as follows: The steps include: (1) Compound 1 is dissolved in an organic solvent I, and a base a and 2-(trimethylsilyl)ethoxymethyl chloride are added at -5 to 5°C. After the addition is complete, the mixture is reacted at 15 to 60°C for 10 to 40 hours. After the reaction is complete, the resulting reaction solution is post-treated to obtain Compound 2; (2) Compound 2, zinc chloride and organic solvent II are mixed evenly, and a portion of cyclopropylmagnesium bromide solution is added under the protection of an inert gas. After the addition is complete, a palladium catalyst is added, and the temperature is raised to 40 to 60° C., and the remaining cyclopropylmagnesium bromide solution is added. After the addition is completed, the reaction is carried out at 15 to 60° C. for 0.5 to 3 hours. After the reaction is completed, the resulting reaction solution is post-treated to obtain compound 3; (3) Compound 3 is dissolved in a hydrochloric acid ethyl acetate solution, stirred at 15-60°C for 8-16 hours, the resulting reaction solution is spun dry, then dissolved in dichloromethane, base b is added, stirred at 15-60°C for 2-4 hours; then ammonia water is added, stirred at 15-60°C for 8-16 hours; after the reaction is completed, the resulting reaction solution is post-treated to obtain the target compound 4, i.e., 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine.

2. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 1, characterized in that: In step (1), The organic solvent I is selected from one or more of acetonitrile, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, toluene, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric acid triamide or N-methylpyrrolidone; And / or the base a is selected from one or more of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium acetate, sodium tert-butoxide or potassium tert-butoxide.

3. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 1, characterized in that: In step (1), the molar ratio of compound 1, base a and 2-(trimethylsilyl)ethoxymethyl chloride is 1:1.8-2.2:1-1.

4.

4. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 1, characterized in that: In step (2), The organic solvent II is selected from one or more of tetrahydrofuran, diethyl ether or methyl tert-butyl ether; and / or the inert gas is nitrogen and / or argon; And / or the palladium catalyst is tetrakis(triphenylphosphine)palladium and / or tris(dibenzylideneacetone)dipalladium.

5. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 1, characterized in that: In step (2), the mass volume ratio of the compound 2 to the organic solvent II is 1:5-40 g / mL.

6. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 1, characterized in that: In step (2), the molar ratio of the compound 2, zinc chloride, palladium catalyst and cyclopropylmagnesium bromide is 1:0.4-0.6:0.02-0.08:2.5-3.

7. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 1, characterized in that: In step (3), The base b is selected from one or more of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium acetate, sodium tert-butoxide or potassium tert-butoxide; And / or the molar ratio of the compound 3 to the base b is 1:2-6.

8. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to any one of claims 1 to 7, characterized in that: In step (1), the base a is potassium carbonate, and the molar ratio of compound 1, potassium carbonate and 2-(trimethylsilyl)ethoxymethyl chloride is 1:2:1.2; In step (2), the palladium catalyst is tetrakis(triphenylphosphine)palladium, and the molar ratio of compound 2, zinc chloride, tetrakis(triphenylphosphine)palladium and cyclopropylmagnesium bromide is 1:0.5:0.05:2.7; In step (3), the base b is potassium carbonate, and the molar ratio of compound 3 to potassium carbonate is 1:

4.

9. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 1, characterized in that: In step (1), the post-treatment process includes: adding ice water to the reaction solution, extracting with organic solvent III, combining the organic phases, drying, filtering, concentrating, and purifying the crude product to obtain compound 2; And / or in step (2), the post-treatment process includes: adding water to the reaction solution, extracting with organic solvent IV, combining the organic phases, drying, filtering, concentrating, and purifying the crude product to obtain compound 3; And / or in step (3), the post-treatment process includes: adding water to the reaction solution, extracting with an organic solvent V, combining the organic phases, drying, filtering, concentrating, and purifying the crude product to obtain the target compound 4.

10. The method for synthesizing 5-bromo-3-cyclopropyl-1H-pyrrolo[2,3-b]pyridine according to claim 9, characterized in that: The organic solvent III is selected from one or more of ethyl acetate, butyl acetate, chloroform, toluene, dichloromethane, and dichloroethane; and / or the organic solvent IV is selected from one or more of isooctane, cyclohexane, hexane, petroleum ether, n-pentane and isopentane; And / or the organic solvent V is selected from one or more of isooctane, cyclohexane, hexane, petroleum ether, n-pentane and isopentane.